Abstract
Diabetes mellitus (DM) is one of the most prevalent metabolic disorders that poses a global threat to human health. It can lead to complications in multiple organs and tissues, owing to its wide-ranging impact on the human body. Diabetic cardiomyopathy (DCM) is a specific cardiac manifestation of DM, which is characterized by heart failure in the absence of coronary heart disease, hypertension and valvular heart disease. Given that oxidative stress is a key factor in the pathogenesis of DCM, intervening to mitigate oxidative stress may serve as a therapeutic strategy for managing DCM. Naringenin is a natural product with anti-oxidative stress properties that can suppress oxidative damage by regulating various oxidative stress signaling pathways. In this review, we address the relationship between oxidative stress and its primary signaling pathways implicated in DCM, and explores the therapeutic potential of naringenin in DCM.
Keywords:
Diabetic cardiomyopathy; NF-κB; NOX; Nrf2; REAGE; naringenin; oxidative stress; signal pathways.
MeSH terms
-
Antioxidants / therapeutic use
-
Diabetes Mellitus*
-
Diabetic Cardiomyopathies* / drug therapy
-
Flavanones* / therapeutic use
-
Humans
-
Oxidative Stress
Substances
-
Antioxidants
-
naringenin
-
Flavanones
Grants and funding
This research was funded by the fund (KeyME-KeyME-2020-004) of Key Laboratory of medical electrophysiology, and the fund (xtcx2019-13) of Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease of Sichuan Province; Southwest Medical University. Sichuan Science and Technology Program (2022YFS0610), Luzhou Municipal Peoples Government-Southwest Medical University Science and Technology Strategic Cooperation (2021LZXNYD-J33). Sichuan Science and Technology Program (2022YFS0610, 2023NSFSC0576), Gulin County People's Hospital – Affiliated Hospital of Southwest Medical University Science and Technology strategic Cooperation (2022GLXNYDFY13). Hejiang People's Hospital – Southwest Medical University Science and Technology Strategic Cooperation Project (2021HJXNYD13) and 2022-N-01-33 project of China International Medical Foundation.